Nature11d
Goldie–Coldman and bevacizumab beyond disease progression
Bevacizumab is a recombinant humanized monoclonal antibody that binds VEGF-A and targets tumor associated angiogenesis by preventing receptor binding. Although the precise mechanism of action of ...
Hosted on MSN29d
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
These findings align with the proposed mechanism of action for the therapy that involves ... amezalpat in conjunction with atezolizumab and bevacizumab in a pivotal Phase III trial for ...
drugtargetreview.com13d
Coherus announces positive Phase II results for liver cancer treatment
Casdozokitug, combined with atezolizumab and bevacizumab, shows durable responses and a 17.2% complete response rate in HCC ...
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response ...
Pharmaceutical Technology29d
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective ...